Lemtrada 'Behaves Like Chemotherapy For MS' Suggests 5-Year Efficacy Data
This article was originally published in Scrip
Around two thirds of patients on Genzyme's multiple sclerosis treatment Lemtrada (alemtuzumab) need no additional treatment up to four years after the two courses of infusion that make up its standard treatment schedule, according to Genzyme's Mike Panzara, therapeutic area head of MS, neurology and ophthalmology.
You may also be interested in...
The continuing benefits of Sanofi’s multiple sclerosis therapy Lemtrada six years after two short courses bolster the case for its use early in the course of the disease.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.